-
The evolving field of post-transplant therapy in multiple myeloma
Sarah A Holstein, & Philip L McCarthy
Clinical Trail Outcomes: Clinical Investigation
-
The evolving field of post-transplant therapy in multiple myeloma
Sarah A Holstein, & Philip L McCarthy
Clinical Trail Outcomes: Clinical Investigation
-
The evolving field of post-transplant therapy in multiple myeloma
Sarah A Holstein, & Philip L McCarthy
Clinical Trail Outcomes: Clinical Investigation
-
The evolving field of post-transplant therapy in multiple myeloma
Sarah A Holstein, & Philip L McCarthy
Clinical Trail Outcomes: Clinical Investigation
-
The evolving field of post-transplant therapy in multiple myeloma
Sarah A Holstein, & Philip L McCarthy
Clinical Trail Outcomes: Clinical Investigation
-
The evolving field of post-transplant therapy in multiple myeloma
Sarah A Holstein, & Philip L McCarthy
Clinical Trail Outcomes: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Inhaled corticosteroids: the last 5 years
Hengameh H Raissy, H William Kelly
Review: Clinical Trail Outcomes: Clinical Investigation
-
Inhaled corticosteroids: the last 5 years
Hengameh H Raissy, H William Kelly
Review: Clinical Trail Outcomes: Clinical Investigation
-
Inhaled corticosteroids: the last 5 years
Hengameh H Raissy, H William Kelly
Review: Clinical Trail Outcomes: Clinical Investigation
-
Inhaled corticosteroids: the last 5 years
Hengameh H Raissy, H William Kelly
Review: Clinical Trail Outcomes: Clinical Investigation
-
Inhaled corticosteroids: the last 5 years
Hengameh H Raissy, H William Kelly
Review: Clinical Trail Outcomes: Clinical Investigation
-
Inhaled corticosteroids: the last 5 years
Hengameh H Raissy, H William Kelly
Review: Clinical Trail Outcomes: Clinical Investigation
-
Zoledronic acid in conjunction with chemotherapy: bisphosphonate gives fresh hope for newly diagnosed multiple myeloma patients
News and Views: Clinical Investigation
-
Zoledronic acid in conjunction with chemotherapy: bisphosphonate gives fresh hope for newly diagnosed multiple myeloma patients
News and Views: Clinical Investigation
-
Zoledronic acid in conjunction with chemotherapy: bisphosphonate gives fresh hope for newly diagnosed multiple myeloma patients
News and Views: Clinical Investigation
-
Zoledronic acid in conjunction with chemotherapy: bisphosphonate gives fresh hope for newly diagnosed multiple myeloma patients
News and Views: Clinical Investigation
-
Zoledronic acid in conjunction with chemotherapy: bisphosphonate gives fresh hope for newly diagnosed multiple myeloma patients
News and Views: Clinical Investigation
-
Zoledronic acid in conjunction with chemotherapy: bisphosphonate gives fresh hope for newly diagnosed multiple myeloma patients
News and Views: Clinical Investigation
-
PARP inhibition: opening up new horizons?
Florian Heitz, Andreas du Bois
Editorial: Clinical Investigation
-
PARP inhibition: opening up new horizons?
Florian Heitz, Andreas du Bois
Editorial: Clinical Investigation
-
PARP inhibition: opening up new horizons?
Florian Heitz, Andreas du Bois
Editorial: Clinical Investigation
-
PARP inhibition: opening up new horizons?
Florian Heitz, Andreas du Bois
Editorial: Clinical Investigation
-
PARP inhibition: opening up new horizons?
Florian Heitz, Andreas du Bois
Editorial: Clinical Investigation
-
PARP inhibition: opening up new horizons?
Florian Heitz, Andreas du Bois
Editorial: Clinical Investigation
-
Strategies to treat sepsis: old and new
Steven P LaRosa, Steven M Opal
Therapeutic Prospective: Clinical Investigation
-
Strategies to treat sepsis: old and new
Steven P LaRosa, Steven M Opal
Therapeutic Prospective: Clinical Investigation
-
Strategies to treat sepsis: old and new
Steven P LaRosa, Steven M Opal
Therapeutic Prospective: Clinical Investigation
-
Strategies to treat sepsis: old and new
Steven P LaRosa, Steven M Opal
Therapeutic Prospective: Clinical Investigation
-
Strategies to treat sepsis: old and new
Steven P LaRosa, Steven M Opal
Therapeutic Prospective: Clinical Investigation
-
Strategies to treat sepsis: old and new
Steven P LaRosa, Steven M Opal
Therapeutic Prospective: Clinical Investigation